» Home » Research 
Print this pageEmail this page URLConvert this page to PDF

Publications by this IRC author

(Publications from the same author but with another affiliation than IRC cannot be displayed here)

For copyright reasons, PDF-versions of our publications are available on the intranet only (login required  ). If you would like to receive a reprint of an IRC paper, please copy/paste the reference in the
reprint request form 

Click the UGent logo to retrieve publications of Kenny Roose in the UGent bibliography

Van den Hoecke, S, Ballegeer, M, Vrancken, B, Deng, L, Job, ER, Roose, K, Schepens, B, Van Hoecke, L, Lemey, P, Saelens, X.
In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression
mBio 12, e0074521, 2021. (Epub 2021 Aug 31)

Van Hoecke, L, Van Lint, S, Roose, K, Van Parys, A, Vandenabeele, P, Grooten, J, Tavernier, J, De Koker, S, Saelens, X.
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
Nat Commun 9, 3417, 2018. (Epub 2018 Aug 24)

De Koker, S, Van Hoecke, L, De Beuckelaer, A, Roose, K, Deswarte, K, Willart, MA, Bogaert, P, Naessens, T, De Geest, BG, Saelens, X, Lambrecht, BN, Grooten, J.
Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12
Sci Rep 7, 5986, 2017. (Epub 2017 Jul 20)

Deng, L, Roose, K, Job, ER, De Rycke, R, Van Hamme, E, Goncalves, A, Parthoens, E, Cicchelero, L, Sanders, N, Fiers, W, Saelens, X.
Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus
J Control Release 264, 55-65, 2017. (Epub 2017 Oct 28)

Udhayakumar, VK, De Beuckelaer, A, McCaffrey, J, McCrudden, CM, Kirschman, JL, Vanover, D, Van Hoecke, L, Roose, K, Deswarte, K, De Geest, BG, Lienenklaus, S, Santangelo, PJ, Grooten, J, McCarthy, HO, De Koker, S.
Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide
Adv Healthc Mater 6, 13, 2017. (Epub 2017 Apr 24)

De Beuckelaer, A, Pollard, C, Van Lint, S, Roose, K, Van Hoecke, L, Naessens, T, Udhayakumar, VK, Smet, M, Sanders, N, Lienenklaus, S, Saelens, X, Weiss, S, Vanham, G, Grooten, J, De Koker, S.
Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses
Mol Ther 24, 2012-2020, 2016. (Epub 2016 Aug 10)

Maelfait, J, Roose, K, Vereecke, L, Mc Guire, C, Sze, M, Schuijs, MJ, Willart, M, Itati Ibanez, L, Hammad, H, Lambrecht, BN, Beyaert, R, Saelens, X, van Loo, G.
A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection
PLoS Pathog 12, e1005410, 2016. (Epub 2016 Jan 27)

Cho, KJ, Schepens, B, Seok, JH, Kim, S, Roose, K, Lee, JH, Gallardo, R, Van Hamme, E, Schymkowitz, J, Rousseau, F, Fiers, W, Saelens, X, Kim, KH.
Structure of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus in Complex with a Protective Monoclonal Antibody
J Virol 89, 3700-3711, 2015. (Epub 2015 Jan 21)

De Baets, S, Verhelst, J, Van den Hoecke, S, Smet, A, Schotsaert, M, Job, ER, Roose, K, Schepens, B, Fiers, W, Saelens, X.
A GFP Expressing Influenza A Virus to Report In Vivo Tropism and Protection by a Matrix Protein 2 Ectodomain-Specific Monoclonal Antibody
PLoS One 10, e0121491, 2015. (Epub 2015 Mar 27)

Deng, L, Ibanez, LI, Van den Bossche, V, Roose, K, Youssef, SA, de Bruin, A, Fiers, W, Saelens, X.
Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages
PLoS One 10, e0126650, 2015. (Epub 2015 May 14)

Cardoso, FM, Ibanez, LI, Van den Hoecke, S, De Baets, S, Smet, A, Roose, K, Schepens, B, Descamps, FJ, Fiers, W, Muyldermans, S, Depicker, A, Saelens, X.
Single domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge
J Virol 88, 8278-8296, 2014. (Epub 2014 May 14)

Christopoulou, I, Roose, K, Ibanez, LI, Saelens, X.
Influenza vaccines to control influenza-associated bacterial infection: where do we stand?
, , 2014. (Epub 2014 Sep 11)

Couceiro, JR, Gallardo, R, De Smet, F, De Baets, G, Baatsen, P, Annaert, W, Roose, K, Saelens, X, Schymkowitz, J, Rousseau, F.
Sequence-dependent internalisation of aggregating peptides
J Biol Chem 290, 242-258, 2014. (Epub 2014 Nov 12)

De Baets, S, Roose, K, Schepens, B, Saelens, X.
Presenting heterologous epitopes with hepatitis B core-based virus-like particles
In Virus-like Particles in Vaccine Development. (Buonaguro, FM, Buonaguro, L, eds.), London, Future Medicine Ltd. , pp. 68-84, 2014. (Epub 2014 Jan)

Schepens, B, Sedeyn, K, Vande Ginste, L, De Baets, S, Schotsaert, M, Roose, K, Houspie, L, Van Ranst, M, Gilbert, B, van Rooijen, N, Fiers, W, Piedra, P, Saelens, X.
Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein
EMBO Mol Med 6, 1436-1454, 2014. (Epub 2014 Oct 8)

De Baets, S, Schepens, B, Sedeyn, K, Schotsaert, M, Roose, K, Bogaert, P, Fiers, W, Saelens, X.
Recombinant influenza virus carrying the RSV F85-93 CTL epitope reduces respiratory syncytial virus replication in mice
J Virol 87, 3314-3323, 2013. (Epub 2013 Jan 9)

Ibanez, LI, Roose, K, De Filette, M, Schotsaert, M, De Sloovere, J, Roels, S, Pollard, C, Schepens, B, Grooten, J, Fiers, W, Saelens, X.
M2e displaying virus-like particles with associated RNA promote T Helper 1 type adaptive immunity against Influenza A
PLoS One 8, e59081, 2013. (Epub 2013 Mar 18)

Roose, K, De Baets, S, Schepens, B, Saelens, X.
Presenting heterologous epitopes with hepatitis B core-based virus-like particles
Expert Rev Vaccines 12, 183-198, 2013. (Epub 2013 Feb)

Maelfait, J, Roose, K, Bogaert, P, Sze, M, Saelens, X, Pasparakis, M, Carpentier, I, van Loo, G, Beyaert, R.
A20 (Tnfaip3) deficiency in myeloid cells protects against Influenza A virus infection
PLoS Pathog 8, e1002570, 2012. (Epub 2012 Mar 1)

Roose, K, Schotsaert, M, El Bakkouri, K, Schepens, B, Fiers, W, Saelens, X.
Cutting edge approaches towards novel and cross-protective influenza vaccines
In Development of novel vaccines. (von Gabain, A, Klade, C, eds.), Wien, Springer-Verlag, pp. 205-233, 2012. (Epub )

De Filette, M, Ysenbaert, T, Roose, K, Schotsaert, M, Roels, S, Goossen, E, Schepens, B, Fiers, W, Saelens, X.
Antiserum against the conserved nine-amino-acid N-terminal peptide of influenza A virus matrix protein 2 is not immuno-protective
J Gen Virol 92, 301-306 , 2011. (Epub 2010 Oct 21)

Fiers, W, De Filette, M, El Bakkouri, K, Schepens, B, Roose, K, Schotsaert, M, Birkett, A, Saelens, X.
M2e-based universal influenza A vaccine
Vaccine 27, 6280-6283, 2009. (Epub 2009 Oct 23)

Roose, K, Fiers, W, Saelens, X.
Pandemic preparedness: Toward a universal influenza vaccine
Drug News Perspect 22, 80-92, 2009. (Epub ---)

Bredan, A, Roose, K, Schotsaert, M, Saelens, X.
Chapter 18. Vaccine development by recombinant DNA technology. Part I: DNA Vaccines
In The Oea Review of Medicine. (Hadeli, K, Benamer, H, eds.), Tripoli, Oea Medical Publisher, 419-434, 2008. (Epub ---)

Bredan, A, Roose, K, Schotsaert, M, Saelens, X.
Chapter 19. Vaccine development by recombinant DNA technology. Part II: Virus-like Particles
In The Oea Review of Medicine. (Hadeli, K, Benamer, H, eds.), Tripoli, Oea Medical Publisher, 435-453, 2008. (Epub ---)

De Filette, M, Martens, W, Roose, K, Deroo, T, Vervalle, F, Bentahir, M, Vandekerckhove, J, Fiers, W, Saelens, X.
An Influenza A vaccine based on tetrameric ectodomain of Matrix Protein 2
J Biol Chem 283, 11382-11387, 2008. (Epub 2008 Feb 5)

Back to previous page

Export in CSV

To top

What do these icons mean?

pdf file (800 kb)